Filing Details
BriaCell Therapeutics Corp. (NASDAQ:BCTX) filed its annual report (Form 10-K) with the Securities and Exchange Commission on October 28, 2026.
The Healthcare company's annual report covers fiscal year 2026.
10k filedNASDAQ:BCTX
BriaCell Therapeutics Corp. (BCTX) Files Annual Report with SEC
BriaCell Therapeutics Corp. (NASDAQ:BCTX) filed its annual report (Form 10-K) with the Securities and Exchange Commission on October 28, 2026.
At publication ·
What changed
BriaCell Therapeutics Corp. (NASDAQ:BCTX) · 10k filed
- Form
- 10-K
At a glance
Key takeaways
- BriaCell Therapeutics Corp. filed its 2026 annual report (Form 10-K) with the SEC on October 28, 2026.
- The company's stock trades at $3.50 with a market capitalization of $19.5 million.
- The 10-K contains detailed financial statements, management analysis, risk factors, and business segment information for the fiscal year.
Market Context
BriaCell Therapeutics Corp.'s stock currently trades at $3.50 with a market capitalization of $19.5M.
The 10-K is the most comprehensive annual report a public company files, containing detailed financial statements, management discussion and analysis (MD&A), risk factors, and business segment breakdowns. For BriaCell Therapeutics Corp. investors, the 10-K provides depth that quarterly reports don't — including full-year trends, long-term debt schedules, and off-balance-sheet items.
Key sections to review: MD&A for management's narrative on performance, risk factors for newly disclosed threats, and the notes to financial statements for accounting changes that could affect reported earnings.
All SEC filings for BriaCell Therapeutics Corp. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View BCTX Stock Page
Frequently Asked Questions
Where can I read BCTX's SEC filings?
Browse all filings on our BCTX SEC filings page.
What types of SEC filings does BriaCell Therapeutics Corp. file?
Public companies like BriaCell Therapeutics Corp. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
